1	Simple and economical RNA extraction and storage packets for viral detection from serum
2	or plasma
3	
4	Running Title: Economical RNA extraction and storage packets
5	
6	Sarah Hernandez <sup>1</sup> , Fátima Cardozo <sup>2</sup> , David R. Myers <sup>3,4</sup> , Alejandra Rojas <sup>5</sup> , Jesse J. Waggoner <sup>1,6,#</sup>
7	
8	<sup>1</sup> Emory University Department of Medicine, Division of Infectious Diseases, Atlanta, Georgia,
9	USA
10	<sup>2</sup> Universidad Nacional de Asunción, Instituto de Investigaciones en Ciencias de la Salud,
11	Departamento de Salud Pública, Paraguay
12	<sup>3</sup> Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia
13	Institute of Technology, Atlanta, Georgia, USA
14	<sup>4</sup> Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta, Emory
15	University Department of Pediatrics, Atlanta, Georgia, USA
16	<sup>5</sup> Universidad Nacional de Asunción, Instituto de Investigaciones en Ciencias de la Salud,
17	Departamento de Producción, Paraguay
18	<sup>6</sup> Rollins School of Public Health, Department of Global Health, Atlanta, Georgia, USA
19	
20	# Corresponding Author: Jesse J. Waggoner, 1760 Haygood Drive NE, Room E-169, Bay E-1,
21	Atlanta, GA, 30329. Email: jjwaggo@emory.edu. Telephone: +1 (404) 712-2360
22	
23	

- 24 Word Count
- 25 Abstract, 248; Total, 5564
- 26 Inserts
- 27 Tables 2, Supplemental Tables, 5
- 28 Figures 5, Supplemental Figures, 2

#### 29 Abstract

30 RNA extraction is an essential step for detection and surveillance of common viral pathogens. 31 Currently, sample processing and RNA extraction are costly and rely on proprietary materials 32 that are difficult to acquire, maintain, and safely discard in low-resource settings. We developed 33 an economical RNA extraction and storage protocol that eliminates the use of instrumentation, 34 expensive materials, and cold chain requirements. Through an iterative process, we optimized 35 viral lysis and RNA binding to and elution from glass fiber membranes. Protocol changes were 36 evaluated by testing eluates in virus-specific real-time RT-PCRs (rRT-PCRs). Efficient, non-37 toxic viral lysis was achieved with a sucrose buffer including KCl, proteinase K and carrier 38 RNA. Glass fiber membranes demonstrated concentration-dependent RNA binding of three 39 arthropod-borne RNA viruses (arboviruses): dengue, chikungunya and Oropouche. Membrane 40 binding was significantly increased in an acidic arginine binding buffer. For the clinical 41 evaluation, 36 dengue virus (DENV)-positive serum samples were extracted in duplicate in the optimized protocol and results were compared to a commercial method. DENV RNA was 42 43 successfully extracted from 71/72 replicates (98.6%) in the extraction packets, and rRT-PCR Ct 44 values correlated between the techniques. Five clinical samples were selected to evaluate 45 ambient-temperature storage up to 7 days on dried glass fiber membranes. DENV RNA was 46 stable at 1, 3 and 7 days post extraction, with a mean difference in eluate RNA concentration of 47  $0.14 \log_{10}$  copies/µL. At a cost of \$0.08 /sample, RNA extraction and storage packets address 48 key limitations to available protocols and may increase capacity for molecular detection of RNA 49 viruses.

50

51 Keywords: ribonucleic acid, extraction, dengue virus, molecular testing

52 RNA viruses are the largest group of human viral pathogens and the most common cause of emerging infectious disease outbreaks.<sup>1, 2</sup> Clinical management and disease containment rely on 53 54 accurate laboratory diagnosis. For many RNA viruses, molecular methods provide the most 55 sensitive and specific acute-phase diagnostics<sup>3-7</sup>, and RNA extraction remains a crucial step in 56 sample preparation that ensures optimal performance of such methods. However, extraction 57 presents many challenges owing to the relative instability of RNA compared to DNA and the 58 presence of RNA degrading enzymes (RNases) and PCR inhibitors in clinical samples.<sup>8-10</sup> Extraction is generally performed using commercial kits that are costly and rely on proprietary 59 materials that can be difficult to obtain in low-resource settings or emerging markets.<sup>11, 12</sup> Kits 60 61 often require the use of dedicated instruments, corrosive and hazardous chemicals, and -80°C storage of the resulting eluate if testing will not be performed within 24 hours.<sup>8-10, 13, 14</sup> As a 62 63 result, RNA extraction and storage remain major barriers to the implementation and use of 64 molecular methods in low-resource settings.

65

66 Arboviruses comprise the subset of RNA viruses transmitted by infected arthropod vectors such 67 as mosquitoes and ticks. These have resulted in large, recent outbreaks caused by the 68 introduction of viruses into naïve populations [e.g., chikungunya virus (CHIKV) and Zika virus (ZIKV) in the Americas in 2014-2016]<sup>15-18</sup> or re-emergence of viruses in populations residing in 69 endemic regions [e.g., vellow fever virus (YFV) and dengue virus (DENV)].<sup>19-23</sup> Of the 70 71 arboviruses, DENV is responsible for the greatest burden of human disease, causing an estimated 100 million symptomatic infections (dengue cases) per year spread over 125 countries.<sup>24</sup> Dengue 72 73 presents with nonspecific, systemic symptoms that cannot be clinically differentiated from other 74 causes of an acute febrile illness, and diagnostic confirmation relies on the availability of

75	laboratory tests. <sup>7, 20</sup> However, in endemic countries such as Paraguay, DENV causes large
76	seasonal outbreaks that exhaust laboratory reagent supply and testing capacity, resulting in under
77	detection and potentially worse clinical outcomes.4, 25, 26
78	
79	In this study, we sought to address barriers to RNA virus detection that result from available
80	extraction methods and the inherent challenges of working with RNA. We developed a simple,
81	safe, and economical protocol for RNA extraction and storage from serum and plasma in
82	resource-limited settings. The protocol was developed and optimized using contrived DENV
83	clinical samples and RNA from species representing the 3 predominant genera of arboviruses:
84	DENV, a flavivirus; CHIKV, an alphavirus; and Oropouche virus (OROV), an orthobunyavirus.
85	Clinical evaluation of the optimized protocol was then performed on a set of 36 acute-phase
86	samples from confirmed dengue cases in Paraguay.
87	
88	

# 89 **Results**

90 Viral lysis. Four experimental lysis buffers (deionized water, STET (8% Sucrose, 5% Triton<sup>™</sup>X-91 100, 50mM Tris-HCl, and 50 mM EDTA), Sodium Dodecyl Sulfate-NaCl, and sucrose buffer) 92 were evaluated for the ability to lyse DENV, followed by completion of RNA extraction in a 93 commercial spin column protocol (QIAamp Viral RNA Mini Kit, Qiagen). SDS-NaCl and 94 sucrose solutions performed similarly, yielding earlier DENV cycle threshold (Ct) values 95 (indicating increased RNA yield) by rRT-PCR (Table S1). To eliminate potential SDS inhibition 96 of downstream molecular testing, sucrose buffer was chosen as the lysis buffer for further 97 experiments. To further enhance RNA recovery and prevent degradation, varying amounts of

98	poly-A carrier RNA and proteinase K were added to the lysis buffer. In side-by-side				
99	comparisons, carrier RNA ( $2.5\mu g$ /sample) and proteinase K ( $5.0\mu g$ /sample) independently				
100	increased RNA recovery. Higher concentrations of carrier RNA and proteinase K in the lysis				
101	mixture did not enhance RNA recovery (5 and 10µg/sample, respectively; Tables S2 and S3). In				
102	addition, the impact of lysis incubation on RNA recovery at room temperature was tested at				
103	various time durations from 1 to 60 minutes. Samples were stable for up to one hour in lysis				
104	mixture, however, longer incubation times did not result in increased RNA recovery after ten-				
105	minute sample incubation at room temperature (data not shown). Based on these data, a ten-				
106	minute incubation period was selected for the final procedure.				
107					
108	Membranes. Extraction packets were assembled as shown in Figure 1. Whatman 3, Fusion 5,				
109	and glass fiber (GF/D) membranes were evaluated as the RNA binding membrane. To compare				
110	RNA recovery from the different membranes, $15\mu L$ of purified DENV, CHIKV, and OROV				
111	RNA were mixed with lysis buffer and ethanol and added to packets containing one of the 3				
112	membranes. RNA was then eluted and tested by rRT-PCR. RNA recovery was successful for all				
113	viruses and concentrations on the GF/D membranes (12/12), whereas one extraction failed with				
114	both the Whatman 3 and Fusion 5 membranes (11/12 each; Table 1). Ct values were also lowest				
115	for RNA recovered from GF/D membranes, and based on these data, the GF/D membrane was				
116	selected for inclusion in the final RNA extraction packet.				
117					
118	Amino acid binding buffers. Arginine- and glutamine-based amino acid binding buffers were				
119	assessed as a method to modulate RNA-membrane interactions when the lysate was loaded on				

120 the packet. Contrived DENV-positive serum samples were lysed and then treated with either

121 amino acid buffer. Although results did not differ significantly, arginine treatment yielded 122 increased RNA recovery, with lower Ct values overall and decreased variability (Figure S1). 123 Based on these data, arginine was chosen for future experiments. To further evaluate the impact 124 of arginine binding buffer, DENV, CHIKV and OROV RNA were added to the membranes in 125 either the sucrose lysis buffer or an arginine buffer (plus ethanol in both cases). Relative to 126 sucrose buffer, the arginine buffer demonstrated lower mean Ct values and decreased variability 127 in Ct values with each membrane (Figure 2A). Ct values were significantly lower with the use of 128 arginine buffer when data from all membranes were evaluated together (Figure 2A), and the 129 relative increase in RNA yield is shown in Figure 2B. 130 131 Following the initial analytical evaluation with purified RNA, arginine buffer was evaluated as a 132 viral lysis buffer in place of sucrose buffer. However, testing with contrived DENV samples 133 resulted in worse RNA recovery (Figure S2A). The arginine buffer was subsequently integrated 134 as a binding buffer that is added after incubation of the sample in lysis buffer. This allowed for 135 both successful viral lysis and improved binding of viral RNA to the packet membrane (Figure 136 S2B). With the addition of the arginine buffer to the procedural workflow, MgCl<sub>2</sub> in the sucrose 137 buffer was changed to KCl to harmonize buffer preparations, which had no impact on RNA 138 recovery (Table S4). 139

Final workflow. Figure 3 shows the final extraction packet workflow. 25µL of serum or plasma
is added to a 1.5mL tube with 25µL lysis mixture (2.5µL carrier RNA, 5µL proteinase k and
17.5µL lysis buffer). Following ten-minute incubation at ambient temperature, 100µL of amino
acid binding buffer and 150µL of 90% ethanol are added to the lysate and mixed thoroughly by

144	pipette. The resulting mixture is loaded dropwise onto the packets. Membranes are subsequently			
145	washed with 100 $\mu$ L glycine buffer and transferred by pipette tip to a tube containing 50 $\mu$ L of TE			
146	elution buffer. Membranes are incubated in elution buffer for 1 min and then discarded.			
147				
148	Clinical evaluation. 36 DENV-positive serum samples from Paraguay, collected from 2018-			
149	2020, were selected for the clinical evaluation of the extraction packets. Demographic			
150	information and laboratory data are shown in Table 2. Samples included serotypes DENV-1			
151	(20/36, 55.6%) and DENV-4 (16/36, 44.4%), which were the predominant DENV serotypes in			
152	Paraguay during those years. Viral loads ranged from 4.73 to 8.22 log10 copies/mL of serum.			
153	Samples were extracted in duplicate with the extraction packets (72 total extractions) and once in			
154	an EMAG robotic extraction instrument. DENV RNA was successfully extracted from 71/72			
155	replicates (98.6%) in the extraction packets, and DENV multiplex rRT-PCR Ct values correlated			
156	with results following EMAG extraction (Figure 4, Table S5).			
157				
158	Five DENV-1 samples were then selected for evaluation of RNA stability when stored on GF/D			
159	membranes at room temperature for up to 7 days. RNA was eluted on days 1, 3 and 7, and			
160	DENV RNA concentration in the eluates was calculated in the DENV multiplex rRT-PCR.			
161	Concentrations (Figure 5A) and Ct values (Figure S3) are shown for each time point. The median			
162	DENV RNA concentration in the eluates was 4.43 $log_{10}$ copies/µL on day 0 and 4.57 $log_{10}$			
163	copies/ $\mu$ L on day 7 (0.14 log <sub>10</sub> copies RNA/ $\mu$ L difference). DENV RNA concentration			
164	fluctuated between time points but remained within the expected error for quantitative rRT-PCR			
165	( $\pm 0.5 \log_{10}$ copies, Figure 5B).			
166				

166

167

# 168 **Discussion**

169 This study presents the development of an alternative, low-cost extraction method compatible 170 with downstream rRT-PCR analysis for arboviral detection. Using the basic packet design of a 171 previous method for viral DNA detection<sup>27</sup>, we developed and optimized a protocol that greatly 172 improved extraction efficiency for RNA viruses. Our protocol is suitable for implementation in 173 resource-limited settings as it eliminates the need for expensive proprietary materials, hazardous 174 chemicals, or electricity during the extraction process. The final extraction packet protocol has 175 an estimated cost of \$0.08 /sample and successfully detected 98.7% of DENV-positive clinical 176 samples when compared to a commercial robotic extraction system that has an initial cost of 177 USD \$115,000. Clinical samples were collected during two large DENV outbreaks in Paraguay 178 (DENV-1 in 2018, DENV-4 in 2019-2020). Notably, the range of viral loads in samples that were available for extraction in the current study represent 92.7% of all DENV-positive samples 179 180 with quantifiable viral loads from these two large outbreaks (Ref. 28, DENV-1; manuscript in 181 progress, DENV-4). Samples with viral loads outside of this range were no longer available for 182 extraction. These data indicate the potential utility of extraction packets in a real-world testing 183 scenario outside of a high resource research laboratory.

184

In addition to examining the limitations posed by RNA extraction methods, in this study we
address the temperature constraints of common RNA storage procedures. Existing
methodologies require ultra-low storage temperatures that are costly to maintain and have limited
capacity.<sup>8, 13, 14</sup> In addition, the need for cold chain storage complicates the shipment of samples
from collection sites to reference laboratories. We report an alternative ambient temperature

190 technique where viral RNA is stored directly on the extraction membrane and integrity is 191 maintained for downstream rRT-PCR analysis. This technique demonstrated RNA stability for 192 up to 7 days post viral lysis for 5/5 clinical samples. Success of this technique likely results from 193 washing with highly acidic buffers and drying the membrane, which serve to reduce RNA 194 transesterification and RNase activity.<sup>28, 29</sup> The developed packets, therefore, address major 195 concerns for specimen preparation and provide a robust alternative for extraction and short-term 196 storage of RNA.

197

198 To-date, there are few RNA extraction methods suitable for implementation in low-resource 199 communities, none of which evaluate a system comparable to the extraction packet design.<sup>30-32</sup> 200 Various efforts to provide a sustainable alternative to expensive commercial kits utilize magnetic 201 bead technology or solid-phase extraction methods that include biohazardous reagents. Magnetic 202 bead technologies provide adjustable surface chemistries and ease of use for nucleic acid isolation.<sup>32</sup> However, beads are relatively expensive and may be difficult to acquire and 203 204 implement in limited resource settings. Other solid phase alternatives rely on toxic phenol and/or 205 guanidine-based solutions that inhibit downstream molecular testing and require special handling in the laboratory.<sup>33-35</sup> To both reduce inhibitory reagents in the procedure and utilize safer 206 207 reagents for distribution outside of standard molecular laboratories, we assessed an alternative 208 sucrose-based lysis buffer. Sucrose solutions have been used in various DNA and RNA isolation 209 protocols and have demonstrated a key role in increasing yield of extracted nucleic material and RNA stability, without compromising testing integrity.<sup>36, 37</sup> The RNA packet extraction protocol 210 211 provides a simple alternative that relies on easily accessible reagents, including proteinase K, and 212 can be prepared on site in a field setting.

213

214	In addition to the sucrose buffer, amino acid buffers were also examined as alternative lysis
215	solutions to be used in lieu of chaotropic salts. A previous study found that several amino acid
216	solutions provide favorable alternatives to standard buffers for nucleic acid recovery due to
217	interactions between the amino acid, RNA and silica surface. <sup>38</sup> Positively charged arginine and
218	polar uncharged glutamine were chosen for evaluation within the extraction packet protocol for
219	their distinct chemical properties. In the RNA extraction packets, low-pH arginine buffer
220	improved RNA yield. However, promising analytical findings did not translate to improved
221	DENV RNA recovery from contrived samples when arginine buffer replaced the optimized
222	sucrose buffer in our extraction protocol. A combined protocol, integrating the arginine solution
223	as a binding buffer after lysis in sucrose buffer, leveraged the properties of both solutions. These
224	data demonstrate the applicability of amino acid buffers in RNA extraction protocols and
225	highlight the importance of rigorous clinical evaluation for findings obtained under optimal
226	laboratory conditions.

227

Limitations of the current study include the use of serum and plasma with the extraction packets. These typically require centrifugation for preparation, though represent the most common specimen types for DENV diagnostic testing.<sup>4, 7, 13, 39, 40</sup> The use of carrier RNA and proteinase K within the lysis mixture also require cold storage following reconstitution, but both reagents can be shipped and stored in a lyophilized format. To address these limitations, future studies should evaluate adaptations to the extraction packets for use with whole blood and alternative methods for ambient temperature storage of carrier RNA and proteinase K.

235

Access to reliable and economical RNA extraction methods remains a significant barrier to viral
molecular detection and surveillance. The packets developed during this study provide safe,
economical, and reproducible RNA extraction from clinical samples. These RNA extraction and
storage packets address key limitations to available protocols and may increase capacity for
molecular detection of RNA viruses.

241

242

#### 243 Methods

244 Packet design. The initial physical design of the packet was based on the filtration isolation of 245 nucleic acids (FINA) method, as previously described.<sup>27</sup> Basic packet design consisted of a 246 5.56mm diameter membrane disk, sandwiched between a square blotter pad base (2.5 x 2.5 cm; 247 VWR International, Radnor, PA) and a Parafilm cover with a 3.96mm diameter opening 248 (Research Products International, Mt. Prospect, IL) centered directly above the membrane disk 249 (Figure 1). Packets were assembled with Whatman 3, Fusion 5, and glass microfiber (GF/D) 250 membranes (all from MiliporeSigma, Burlington, MA). The initial extraction protocol consisted 251 of 1) incubating 25µL of serum/plasma with a lysis mixture for 10 minutes, 2) addition of 252 ethanol, 3) addition of the lysate-ethanol mixture to the extraction packet, 4) a single wash with 253 100µL 10X glycine solution (pH 2.7; Polysciences, Warrington, PA), and 5) elution of RNA by 254 transfer of the membrane to a 1.5mL tube containing 50µL10mM TE buffer, pH 8.0 (Teknova, 255 Hollister, CA). Membranes were incubated in TE for one minute and subsequently removed and 256 disposed. Eluates were tested immediately by rRT-PCR or stored at 4°C for up to 24 hours. 257

258 Lysis and binding buffers. Four experimental lysis buffers were evaluated: deionized water, 259 STET (8% Sucrose, 5% Triton<sup>™</sup> X-100, 50mM Tris-HCl, and 50 mM EDTA; Teknova, Hollister, CA). Sodium Dodecyl Sulfate-NaCl,<sup>34</sup> and a sucrose buffer.<sup>36</sup> Lysis buffers were initially 260 261 incorporated into and evaluated with a membrane-based commercial protocol (QiaAMP Viral 262 RNA Mini Kit, Qiagen, Germantown, MD). Contrived DENV samples were either lysed with 263 buffer AVL (as part of the kit) or an experimental lysis buffer and then extracted with the 264 remaining steps in the manufacturer's protocol. Based on these experiments, the sucrose solution 265 was chosen for the lysis buffer. Poly-A carrier RNA (2.5µg/sample, Qiagen, Germantown, MD) 266 and proteinase K (5µg/sample; New England Biolabs, Ipswich, MA) were evaluated as 267 additional components to the lysis mixture. Further experiments used  $25\mu$ L/reaction of lysis 268 mixture containing 17.5 $\mu$ L of lysis buffer, 2.5 $\mu$ L (2.5 $\mu$ g) carrier RNA and 5 $\mu$ L (5.0 $\mu$ g) 269 proteinase K. All sucrose solution components were adjusted in an iterative manner for further 270 optimization. NaCl, MgCl<sub>2</sub>, and KCl were evaluated as different chaotropic salts across a range 271 of concentrations (50mM to 400mM) alongside varying sucrose concentrations (50mM to 272 300mM). Solution pH was also evaluated at neutral and slightly alkaline pH values (7.0, 7.5, and 273 8.0). The optimized sucrose lysis buffer contained 100mM sucrose (1.2 M; Boston BioProducts, 274 Ashland, MA); 50mM Tris-HCL, pH 7.0; 100mM KCl (both from MilliporeSigma, USA). 275

Arginine and glutamine amino acid binding buffers were initially prepared as described.<sup>41</sup> The buffer contained 100mM L-arginine (MilliporeSigma, USA) and 400 mM KCl. Binding buffer pH was optimized across a range from 1.5-9.1, with a final buffer pH of 1.5. Lysis and binding buffers were stored at room temperature. Following preparation, the lysis mixture was used immediately or stored at 4°C until use.

281

282	Clinical samples and RNA stability. DENV-positive clinical samples were collected as part of
283	an ongoing study to detect and characterize arboviral infections in Asunción, Paraguay in
284	collaboration with the Instituto de Investigaciones en Ciencas de la Salud, Universidad Nacional
285	de Asunción (IICS-UNA). <sup>4</sup> Samples were selected for the current study that had detectable and
286	quantifiable DENV viral loads in the DENV multiplex rRT-PCR and had sufficient volume
287	remaining for re-extraction (100 $\mu$ L). All samples had been shipped to Emory on dry ice, stored
288	at -80°C, and thawed at 4°C immediately prior to extraction. For the clinical evaluation, side-by-
289	side extractions were performed with the extraction packets in duplicate and on an EMAG
290	robotic extraction instrument (bioMérieux, Durham, NC). RNA was extracted from $25\mu$ L of
291	sample and eluted into $50\mu$ L for both the packets and comparator extraction protocols. Eluates
292	were tested immediately by rRT-PCR.

293

294 For the stability study, 5 DENV-1 samples with sufficient remaining volume were individually 295 re-extracted with the packets to evaluate RNA stability on days 0, 1, 3, and 7 post extraction. For 296 this evaluation, 8 extraction packets were prepared, with duplicate packets for each time point. 297 On day 0, DENV RNA was completely extracted, eluted off two membranes, and run in the 298 DENV multiplex rRT-PCR to establish a baseline reference. For the remainder of the time 299 points, DENV RNA was extracted with the packets through the glycine wash step and 300 transferred to empty 1.5mL tubes to air dry at ambient temperature for 1 hour. After drying, 301 tubes were closed and stored in airtight plastic bags with desiccant packets. RNA was eluted 302 from dried membranes with 50µL TE buffer on days 1, 3, and 7 following extractions. Eluates 303 were run in the DENV multiplex rRT-PCR for comparison with day 0 results. A four-point

standard curve was included on each run to calculate DENV-1 RNA concentration at each time
 point.<sup>42, 43</sup>

306

307	Reference viral RNAs and contrived samples. Packet membranes were initially evaluated with
308	viral RNA from DENV, CHIKV and OROV. DENV RNA for this portion of the study was a
309	135-base synthesized DENV-2 RNA oligonucleotide containing the DENV multiplex rRT-PCR
310	target sequence (Ultramer RNA, Integrated DNA Technologies, Coralville, IA). For CHIKV and
311	OROV, previously extracted (EMAG) genomic RNA was used. Contrived clinical samples were
312	prepared by spiking negative human serum or plasma (MilliporeSigma, USA) with DENV-
313	positive serum of known concentrations. Aliquots of contrived specimens were prepared and
314	stored at -80°C until use.
315	
316	<b>rRT-PCR.</b> Eluates from optimization and analytical evaluation experiments were tested in a
317	single-reaction multiplex rRT-PCR for ZIKV, CHIKV, and DENV or a singleplex rRT-PCR for
318	OROV, both performed as previously described. <sup>44, 45</sup> For the clinical evaluation, eluates were
319	tested in the DENV multiplex rRT-PCR, which is a serotype-specific assay for DENV detection
320	and quantitation. <sup>42, 43</sup> All rRT-PCR reactions were performed in $20\mu L$ reactions of the
321	SuperScript III Platinum One-Step qRT-PCR kit (Thermo Fisher) containing $5\mu L$ of eluate and
322	run on a Rotor-Gene Q instrument (Qiagen). Positive and negative controls were included on
323	each run, and rRT-PCRs were analyzed and interpreted as previously described. <sup>42-45</sup>
324	
325	Statistics. Basic statistical analyses were performed in Excel (Microsoft, Redmond, WA). Ct
326	values obtained with lysis buffer and arginine binding buffer were compared by unpaired

- 327 student's t test (GraphPad Prism version 9.2, GraphPad, San Diego, CA). Graphs were prepared
- 328 with GraphPad and Excel.

#### 329 Acknowledgements

- 330 This research was supported by the Doris Duke Foundation (Clinical Scientist Development
- 331 Award 2019089) and the National Institute of Allergy and Infectious Diseases (R21AI146443).
- 332 We thank all members of the research team at the Instituto de Investigaciones en Ciencias de la
- 333 Salud, Universidad Nacional de Asunción, and the participants and their family members who
- have contributed to ongoing studies of arboviral infections in Paraguay. We also thank Katherine
- 335 Immergluck, Maxwell Su, and Victoria Stittleburg at Emory University for their assistance over
- the course of this project.

#### 337 **References**

Carrasco-Hernandez, R.; Jácome, R.; López Vidal, Y.; Ponce De León, S., Are RNA Viruses
 Candidate Agents for the Next Global Pandemic? A Review. *ILAR Journal* 2017, *58* (3), 343-358.

Rosenberg, R., Detecting the emergence of novel, zoonotic viruses pathogenic to humans.
 *Cellular and Molecular Life Sciences* 2015, *72* (6), 1115-1125.

- 342 3. Natrajan, M. S.; Rojas, A.; Waggoner, J. J., Beyond Fever and Pain: Diagnostic Methods for
  343 Chikungunya Virus. *Journal of clinical microbiology* 2019.
- Rojas, A.; Cardozo, F.; Cantero, C.; Stittleburg, V.; Lopez, S.; Bernal, C.; Gimenez Acosta, F.
   E.; Mendoza, L.; Pinsky, B. A.; Arevalo de Guillen, I.; Paez, M.; Waggoner, J., Characterization of dengue cases among patients with an acute illness, Central Department, Paraguay. *PeerJ* 2019, 7, e7852.
- 347 5. Waggoner, J. J.; Pinsky, B. A., Zika Virus: Diagnostics for an Emerging Pandemic Threat.
  348 *Journal of clinical microbiology* 2016, *54* (4), 860-7.
- 349 6. Waggoner, J. J.; Rojas, A.; Pinsky, B. A., Yellow Fever Virus: Diagnostics for a Persistent
  350 Arboviral Threat. *Journal of clinical microbiology* 2018, *56* (10).
- 351 7. World Health Organization, *Dengue: guidelines for diagnosis, treatment, prevention and control.* 352 WHO Press: France, 2009.
- 8. Fabre, A. L.; Colotte, M.; Luis, A.; Tuffet, S.; Bonnet, J., An efficient method for long-term
  room temperature storage of RNA. *Eur J Hum Genet* 2014, *22* (3), 379-85.
- Paul, R.; Ostermann, E.; Wei, Q., Advances in point-of-care nucleic acid extraction technologies
  for rapid diagnosis of human and plant diseases. *Biosens Bioelectron* 2020, *169*, 112592.
- Tan, S. C.; Yiap, B. C., DNA, RNA, and protein extraction: the past and the present. *J Biomed Biotechnol* 2009, 2009, 574398.
- 11. Domingo, C.; Niedrig, M.; Teichmann, A.; Kaiser, M.; Rumer, L.; Jarman, R. G.; Donoso Mantke, O., 2nd international external quality control assessment for the molecular diagnosis of Dengue
   infections. *PLoS neglected tropical diseases* 2010, *4* (10), e833.
- 362 12. Satyanarayana, M., Material shortages hamper testing for novel coronavirus. *C&EN* 2020, *98*363 (12), 6.
- 364 13. Centers for Disease Control and Prevention, CDC DENV-1-4 Real-Time RT-PCR Assay:
   365 Instructions for Use. 2013.
- Centers for Disease Control and Prevention, Trioplex Real-time RT-PCR Assay: Instructions forUse. 2021.
- 368 15. Charrel, R. N.; Leparc-Goffart, I.; Gallian, P.; de Lamballerie, X., Globalization of
- 369 Chikungunya: 10 years to invade the world. Clinical microbiology and infection : the official publication
- 370 of the European Society of Clinical Microbiology and Infectious Diseases 2014, 20 (7), 662-3.

- 371 16. Weaver, S. C.; Lecuit, M., Chikungunya virus and the global spread of a mosquito-borne disease.
  372 *The New England journal of medicine* 2015, *372* (13), 1231-9.
- 373 17. Musso, D.; Gubler, D. J., Zika Virus. *Clinical microbiology reviews* **2016**, *29* (3), 487-524.

374 18. Waggoner, J. J.; Pinsky, B. A., How great is the threat of chikungunya virus? *Expert review of* 375 *anti-infective therapy* 2015, *13* (3), 291-3.

- 376 19. Bhatt, S.; Gething, P. W.; Brady, O. J.; Messina, J. P.; Farlow, A. W.; Moyes, C. L.; Drake, J.
- 377 M.; Brownstein, J. S.; Hoen, A. G.; Sankoh, O.; Myers, M. F.; George, D. B.; Jaenisch, T.; Wint, G.
- R.; Simmons, C. P.; Scott, T. W.; Farrar, J. J.; Hay, S. I., The global distribution and burden of dengue. *Nature* 2013, *496* (7446), 504-7.
- 380 20. Guzman, M. G.; Harris, E., Dengue. Lancet 2015, 385 (9966), 453-65.
- 381 21. Shepard, D. S.; Undurraga, E. A.; Halasa, Y. A.; Stanaway, J. D., The global economic burden
   382 of dengue: a systematic analysis. *The Lancet. Infectious diseases* 2016.
- Zhao, S.; Stone, L.; Gao, D.; He, D., Modelling the large-scale yellow fever outbreak in Luanda,
  Angola, and the impact of vaccination. *PLoS neglected tropical diseases* 2018, *12* (1), e0006158.
- 23. Dexheimer Paploski, I. A.; Souza, R. L.; Tauro, L. B.; Cardoso, C. W.; Mugabe, V. A.; Pereira
  Simoes Alves, A. B.; de Jesus Gomes, J.; Kikuti, M.; Campos, G. S.; Sardi, S.; Weaver, S. C.; Reis,
  M. G.; Kitron, U.; Ribeiro, G. S., Epizootic Outbreak of Yellow Fever Virus and Risk for Human
  Disease in Salvador, Brazil. *Annals of internal medicine* 2017.
- Messina, J. P.; Brady, O. J.; Golding, N.; Kraemer, M. U. G.; Wint, G. R. W.; Ray, S. E.;
  Pigott, D. M.; Shearer, F. M.; Johnson, K.; Earl, L.; Marczak, L. B.; Shirude, S.; Davis Weaver, N.;
  Gilbert, M.; Velayudhan, R.; Jones, P.; Jaenisch, T.; Scott, T. W.; Reiner, R. C.; Hay, S. I., The current and future global distribution and population at risk of dengue. *Nature Microbiology* 2019, *4* (9), 1508-1515.
- 25. Rojas, A.; Aria, L.; de Guillen, Y. A.; Acosta, M. E.; Infanzón, B.; Diaz, V.; López, L.;
- Meza, T.; Riveros, O., Perfil clínico, hematológico y serológico en pacientes con sospecha de dengue del IICS-UNA, 2009-2013. *Mem Inst Investig Cienc Salud* **2016**, *14* (2), 68-74.
- 397 26. Balmaseda, A.; Hammond, S. N.; Tellez, Y.; Imhoff, L.; Rodriguez, Y.; Saborio, S. I.;
- 398 Mercado, J. C.; Perez, L.; Videa, E.; Almanza, E.; Kuan, G.; Reyes, M.; Saenz, L.; Amador, J. J.;
- 399 Harris, E., High seroprevalence of antibodies against dengue virus in a prospective study of
- schoolchildren in Managua, Nicaragua. *Tropical medicine & international health : TM & IH* 2006, 11 (6),
  935-42.
- 402 27. McFall, S. M.; Wagner, R. L.; Jangam, S. R.; Yamada, D. H.; Hardie, D.; Kelso, D. M., A
  403 simple and rapid DNA extraction method from whole blood for highly sensitive detection and
  404 quantitation of HIV-1 proviral DNA by real-time PCR. *Journal of virological methods* 2015, *214*, 37-42.
- 405 28. Seyhan, A. A.; Burke, J. M., Mg2+-independent hairpin ribozyme catalysis in hydrated RNA 406 films. *RNA* **2000**, *6* (2), 189-98.
- 407 29. Perreault, D. M.; Ansly, E. V., Unifying the Current Data on the Mechanism of Cleavage 408 Transesterification of RNA. *Angew. Clrem. Int. Ed. Eng.* 1997, *36*, 432-450.


30. Han, P.; Go, M. K.; Chow, J. Y.; Xue, B.; Lim, Y. P.; Crone, M. A.; Storch, M.; Freemont, P.
S.; Yew, W. S., A high-throughput pipeline for scalable kit-free RNA extraction. *Scientific Reports* 2021, *11* (1).

- 412 31. Wozniak, A.; Cerda, A.; Ibarra-Henríquez, C.; Sebastian, V.; Armijo, G.; Lamig, L.; Miranda,
  413 C.; Lagos, M.; Solari, S.; Guzmán, A. M.; Quiroga, T.; Hitschfeld, S.; Riveras, E.; Ferrés, M.;
  414 Gutiérrez, R. A.; García, P., A simple RNA preparation method for SARS-CoV-2 detection by RT-qPCR.
- 414 Gutierrez, R. A.; Garcia, P., A simple RNA preparation method for SARS-CoV-2 detection by R1-6 415 Scientific Reports **2020**, *10* (1).
- 416 32. Pearlman, S. I.; Leelawong, M.; Richardson, K. A.; Adams, N. M.; Russ, P. K.; Pask, M. E.;
- 417 Wolfe, A. E.; Wessely, C.; Haselton, F. R., Low-Resource Nucleic Acid Extraction Method Enabled by
- 418 High-Gradient Magnetic Separation. ACS Applied Materials & Interfaces 2020, 12 (11), 12457-12467.
- 33. Yaffe, H.; Buxdorf, K.; Shapira, I.; Ein-Gedi, S.; Moyal-Ben Zvi, M.; Fridman, E.;
  Moshelion, M.; Levy, M., LogSpin: a simple, economical and fast method for RNA isolation from
  infected or healthy plants and other eukaryotic tissues. *BMC research notes* 2012, *5*, 45.
- 422 34. Nwokeoji, A. O.; Kilby, P. M.; Portwood, D. E.; Dickman, M. J., RNASwift: A rapid, versatile
  423 RNA extraction method free from phenol and chloroform. *Anal Biochem* 2016, *512*, 36-46.
- Seok, Y.; Batule, B. S.; Kim, M. G., Lab-on-paper for all-in-one molecular diagnostics
  (LAMDA) of zika, dengue, and chikungunya virus from human serum. *Biosens Bioelectron* 2020, *165*, 112400.
- 427 36. Berendzen, K.; Searle, I.; Ravenscroft, D.; Koncz, C.; Batschauer, A.; Coupland, G.; 428 Somssich, I. E.; Ulker, B., A rapid and versatile combined DNA/RNA extraction protocol and its 429 application to the analysis of a novel DNA marker set polymorphic between Arabidopsis thaliana 430 ecotypes Col-0 and Landsberg erecta. *Plant Methods* **2005**, *1* (1), 4.
- 431 37. Anjam, M. S.; Ludwig, Y.; Hochholdinger, F.; Miyaura, C.; Inada, M.; Siddique, S.; Grundler,
  432 F. M. W., An improved procedure for isolation of high-quality RNA from nematode-infected Arabidopsis
  433 roots through laser capture microdissection. *Plant Methods* 2016, *12* (1).
- 434 38. Vandeventer, P. E.; Mejia, J.; Nadim, A.; Johal, M. S.; Niemz, A., DNA Adsorption to and
  435 Elution from Silica Surfaces: Influence of Amino Acid Buffers. *The Journal of Physical Chemistry B*436 2013, *117* (37), 10742-10749.
- 437 39. Waggoner, J. J.; Gresh, L.; Mohamed-Hadley, A.; Balmaseda, A.; Soda, K. J.; Abeynayake, J.;
  438 Sahoo, M. K.; Liu, Y.; Kuan, G.; Harris, E.; Pinsky, B. A., Characterization of Dengue Virus Infections
  439 Among Febrile Children Clinically Diagnosed With a Non-Dengue Illness, Managua, Nicaragua. *The*440 *Journal of infectious diseases* 2017, *215* (12), 1816-1823.
- 441 40. Waggoner, J. J.; Gresh, L.; Vargas, M. J.; Ballesteros, G.; Tellez, Y.; Soda, K. J.; Sahoo, M.
  442 K.; Nunez, A.; Balmaseda, A.; Harris, E.; Pinsky, B. A., Viremia and Clinical Presentation in
  443 Nicaraguan Patients Infected With Zika Virus, Chikungunya Virus, and Dengue Virus. *Clinical infectious*444 *diseases : an official publication of the Infectious Diseases Society of America* 2016, *63* (12), 1584-1590.
- 445 41. Vandeventer, P. E.; Mejia, J.; Nadim, A.; Johal, M. S.; Niemz, A., DNA adsorption to and 446 elution from silica surfaces: influence of amino acid buffers. *J Phys Chem B* **2013**, *117* (37), 10742-9.


- 447 42. Waggoner, J. J.; Abeynayake, J.; Sahoo, M. K.; Gresh, L.; Tellez, Y.; Gonzalez, K.;
- 448 Ballesteros, G.; Guo, F. P.; Balmaseda, A.; Karunaratne, K.; Harris, E.; Pinsky, B. A., Comparison of
- the FDA-approved CDC DENV-1-4 real-time reverse transcription-PCR with a laboratory-developed
- 450 assay for dengue virus detection and serotyping. *Journal of clinical microbiology* **2013**, *51* (10), 3418-20.
- 451 43. Waggoner, J. J.; Abeynayake, J.; Sahoo, M. K.; Gresh, L.; Tellez, Y.; Gonzalez, K.;
- 452 Ballesteros, G.; Pierro, A. M.; Gaibani, P.; Guo, F. P.; Sambri, V.; Balmaseda, A.; Karunaratne, K.;
- 453 Harris, E.; Pinsky, B. A., Single-reaction, multiplex, real-time rt-PCR for the detection, quantitation, and
- 454 serotyping of dengue viruses. *PLoS neglected tropical diseases* **2013**, 7 (4), e2116.
- 455 44. Waggoner, J. J.; Gresh, L.; Mohamed-Hadley, A.; Ballesteros, G.; Davila, M. J.; Tellez, Y.;
- 456 Sahoo, M. K.; Balmaseda, A.; Harris, E.; Pinsky, B. A., Single-Reaction Multiplex Reverse
- Transcription PCR for Detection of Zika, Chikungunya, and Dengue Viruses. *Emerging infectious*
- 458 *diseases* **2016**, *22* (7), 1295-7.
- 459 45. Rojas, A.; Stittleburg, V.; Cardozo, F.; Bopp, N.; Cantero, C.; Lopez, S.; Bernal, C.;
- 460 Mendoza, L.; Aguilar, P.; Pinsky, B. A.; Guillen, Y.; Paez, M.; Waggoner, J. J., Real-time RT-PCR for
- the detection and quantitation of Oropouche virus. *Diagnostic microbiology and infectious disease* **2020**,
- 462 *96* (1), 114894.

463


# 464 Figures



- 466 **Figure 1.** Components and assembly of RNA extraction packets (left) and an assembled packet
- 467 (right). Whatman 3, Fusion 5, and GF/D were evaluated as RNA binding membranes.




468 Figure 2. Amino acid binding buffers improve RNA yield from RNA extraction packets. A) 469 Arginine binding buffer resulted in lower and more consistent rRT-PCR Ct values (improved 470 RNA yield) following DENV, CHIKV and OROV RNA binding to and elution from extraction packets assembled with Whatman 3, Fusion 5, and GF/D membranes. Ct values were 471 472 significantly lower when results from all membranes were pooled (Total; unpaired t-test); 473 comparisons for individual membranes did not reach statistical significance. Box-and-whisker 474 plots display median and range of all values. **B**) Fold increase in RNA yield with the use of 475 arginine binding buffer compared to lysis buffer. Estimated based on expected 3.3 cycle 476 decrease in Ct value for each 10-fold increase in RNA concentration in an rRT-PCR with 100% 477 efficiency.



478

- 479 Figure 3. Optimized packet workflow for RNA extraction and storage. All steps are performed
- 480 at ambient temperature.




481 **Figure 4.** DENV RNA was successfully extracted from clinical samples using economical

482 packets and rRT-PCR Ct values correlated with results following EMAG robotic extractions.

483 Successful RNA extraction was defined as a positive result in the DENV multiplex rRT-PCR.<sup>42,</sup>

- 484 <sup>43</sup> Average Ct values from duplicate packet extractions are graphed versus the Ct following
- 485 EMAG extraction for 36 serum samples positive for DENV-1 (n=20) and DENV-4 (n=16).
- 486 71/72 eluates (98.6%) from the packets had detectable DENV RNA. The sample from which 1 of
- 487 2 replicates was positive is displayed as a half-filled circle.



488

489 Figure 5. DENV RNA stored on dried extraction membranes is stable at ambient temperature for 490 up to 7 days. A) Average DENV-1 RNA concentration in eluates from RNA extraction packets 491 performed in duplicate is displayed for 5 clinical samples that were fully extracted on day 0 or 492 that underwent lysis, addition to GF/D membrane-containing packets, glycine wash, drying and 493 storage at ambient temperature. RNA was then eluted off the dried membranes and tested by 494 rRT-PCR on days 1, 3 and 7. DENV RNA concentration was calculated from a 4-point standard 495 curve included on each run. B) Change in RNA concentration between day 0 and days 1, 3, and 496 7. The shaded region highlights the expected intra-run variability of rRT-PCR (±0.5 log<sub>10</sub> 497 copies/ $\mu$ L). Mean change in concentration across time points (-0.04 log<sub>10</sub> copies/ $\mu$ L) is displayed 498 (red dashed line).

### 499 **Table 1.** rRT-PCR Ct values for RNA of different arboviruses following binding to and elution

500 from Whatman 3, Fusion 5, and GF/D membranes.

Viral RNA	Whatman 3	Fusion 5	GF/D
DENV sample 1	30.13	30.51	30.13
DEIW sample 1	31.49	30.32	30.64
DENV sample 2	38.20	37.18	36.84
DEIW sample 2	a	38.52	36.44
CHIKV sample 1	27.07	27.71	25.05
	25.61	28.38	24.89
CHIKV sample 2	35.34	a	34.02
Cimit + Sumpre 2	35.98	40.80	38.04
OROV sample 1	22.34	23.86	22.97
	23.21	23.22	22.87
OROV sample 2	31.22	33.32	32.75
orto i sumple 2	31.12	33.01	31.50

501 Abbreviations: CHIKV, chikungunya virus; DENV, dengue virus; OROV, Oropouche virus

502 <sup>a</sup> Extraction failed, no Ct value

### 503 **Table 2.** Clinical and DENV laboratory data for 36 clinical samples extracted with the RNA

504 packets.

Category	Result
Total, n	36
Gender, female, n (%)	21 (58.3)
Age, mean (SD)	28.9 (14.1)
Day post-symptom onset, mean (SD)	3.6 (1.6)
Serotype, n (%)	
DENV-1	20 (55.6)
DENV-4	16 (44.4)
Viral load, mean (SD) <sup>a</sup>	7.1 (1.4)
	514

515 Abbreviations: DENV, dengue virus; SD, standard deviation


516 <sup>a</sup> Viral load expressed as log<sub>10</sub> copies/mL serum

## Simple and economical RNA extraction and storage packets for viral detection from serum


or plasma

## **Supplemental Material**


Sarah Hernandez, Fátima Cardozo, David R. Myers, Alejandra Rojas, Jesse J. Waggoner



**Figure S1.** rRT-PCR cycle threshold (Ct) values for lysed DENV-positive serum samples treated with glutamine versus arginine binding buffer prior to addition to extraction packets. All evaluations were done with glass fiber GF/D membranes. Ct values were not significantly different for samples treated with arginine (mean, 35.51; standard deviation, 1.15) versus glutamine (36.21; 1.64; p = 0.2).



**Figure S2. A**) Use of arginine buffer for viral lysis results in reduced RNA yield from extraction packets. **B**) A combined protocol incorporating arginine buffer as a binding buffer after lysis in sucrose buffer results in increased RNA yield compared to an extraction protocol without a binding buffer. Different contrived samples were used on the two runs.



**Figure S3.** Stability of DENV Ct values from 5 clinical samples that were eluted from packets after complete extraction on day 0 or following storage at ambient temperature on the membranes prior to elution on days 1, 3, and 7. Ct values are averages of duplicate extractions tested in the DENV multiplex rRT-PCR. Sample numbers are displayed on the x-axis.

# Table S1. Comparison of DENV Ct values following RNA extraction in experimental lysis

buffers.

Buffer	Replicate	Ct
AVL <sup>a</sup>	1	26.36
	2	26.10
Deionized water	1	33.57
	2	34.07
Sucrose solution	1	28.15
	2	29.14
STET <sup>b</sup>	1	40.64
	2	39.25
SDS-NaCl	1	28.94
	2	28.53

<sup>a</sup> Guanidine thiocyanate-based lysis buffer in the QIAamp Viral RNA Mini Kit

<sup>b</sup> 8% Sucrose, 5% Triton<sup>™</sup>X-100, 50mM Tris-HCl, and 50 mM EDTA

Table S2. Comparison of DENV Ct values following RNA extraction in lysis mixtures with and

without carrier RNA.

	Sucrose	Carrier RNA	Carrier RNA
Replicate	buffer only	(2.5ug/sample)	(5.0ug/sample) <sup>a</sup>
1	29.30	27.27	27.10
2	30.13	26.75	27.79
3	30.27	27.27	_
4	30.08	26.75	-
5	30.51	27.03	-
6	29.72	27.42	_
Average	30.00	27.08	27.45

<sup>a</sup> "—" indicates not tested

Table S3. Comparison of DENV Ct values following RNA extraction in lysis mixtures with and

without proteinase K.

	Sucrose buffer	Proteinase K	Proteinase K
Replicate	+ carrier RNA	(2.5ug/sample)	(5.0ug/sample) <sup>a</sup>
1	32.09	28.34	28.38
2	29.50	27.12	27.24
3	31.14	27.31	27.38
4	33.00	26.23	26.92
5	32.46	26.48	—
6	32.71	26.35	_
Average	31.82	26.97	27.48

<sup>a</sup> "—" indicates not tested

Table S4. Comparison of DENV Ct values following extractions using sucrose lysis buffer

containing 100mM MgCl2 or KCl.

		Sucrose Lysis Buffer		
Sample	Replicate	MgCl <sub>2</sub>	KCl	
1	1	31.99	31.10	
	2	30.90	31.33	
2	1	34.73	34.66	
	2	34.34	34.09	

# Table S5. Ct values following RNA extraction with economical packets and a commercial

robotic system.

Sample	Serotype	Packet	Packet	Average	EMAG
code		Replicate 1	Replicate 2	Packet Ct	Ct
16	D1	24.88	26.22	25.55	17.30
54	D1	28.65	28.60	28.63	23.65
60	D1	30.68	28.34	29.51	22.78
63	D1	27.02	26.92	26.97	21.27
65	D1	26.37	24.31	25.34	21.64
67	D1	26.41	27.48	26.95	21.92
69	D1	31.38	29.51	30.45	27.07
73	D1	25.47	25.29	25.38	21.88
80	D1	28.73	29.83	29.28	24.23
88	D1	23.32	23.31	23.32	18.03
89	D1	25.36	24.75	25.06	19.73
95	D1	35.42	34.31	34.87	29.58
99	D1	24.73	24.17	24.45	18.11
100	D1	27.71	29.13	28.42	23.46
109	D1	26.03	26.04	26.04	20.63
118	D1	25.83	28.00	26.92	22.53
121	D1	33.37	32.48	32.93	31.08
149	D1	25.99	26.49	26.24	21.94
167	D1	29.97	28.91	29.44	23.99
177	D1	30.55	32.17	31.36	28.26
2090	D4	28.66	27.70	28.18	24.81
	1				

2140	D4	33.11	32.18	32.65	24.14
2176	D4	25.89	26.90	26.40	24.20
2257	D4	35.46	34.92	35.19	32.98
2260	D4	32.61	32.58	32.60	38.44
2353	D4	33.24	32.91	33.08	35.30
2410	D4	33.09	31.86	32.48	31.17
2424	D4	31.86	32.49	32.18	30.09
2431	D4	35.12	33.90	34.51	33.15
2435	D4	33.22	32.99	33.11	38.36
2470	D4	29.39	29.56	29.48	26.52
2481	D4	39.01	39.06	39.04	34.95
2499	D4	30.80	30.54	30.67	28.30
8242	D4	N*	36.39	36.39	38.29
8371	D4	36.11	39.53	37.82	37.07
8410	D4	38.29	39.44	38.87	40.50

\* Indicates failed extraction

Abbreviations: EMAG, commercial extraction robot

